Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease.

Date publication

juin 2015

Journal

Alimentary pharmacology & therapeutics

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Luthra P, Peyrin-Biroulet L, Ford AC

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25903741

Résumé

Anti-integrin antibodies are effective therapies for Crohn's disease (CD) and ulcerative colitis (UC). However, these drugs carry theoretical risks of opportunistic infection and malignancy.

Mots clés

Adult, Antibodies, Monoclonal, adverse effects, Antibodies, Monoclonal, Humanized, immunology, Clinical Trials as Topic, Colitis, Ulcerative, drug therapy, Crohn Disease, drug therapy, Humans, Inflammatory Bowel Diseases, drug therapy, Integrins, administration & dosage, Natalizumab, Neoplasms, chemically induced, Opportunistic Infections, chemically induced, Prospective Studies

Référence

Aliment. Pharmacol. Ther.. 2015 Jun;41(12):1227-36